View More Recent Stories

Nov 12, 2016 04:30PM Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis
Nov 10, 2016 08:00AM UCB Family Epilepsy Scholarship Program™ Announces 2016 Recipients
Sep 26, 2016 04:01PM Amgen (AMGN), UCB Announce FDA Acceptance of BLA For Romosozumab
Sep 26, 2016 04:00PM Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab
Sep 20, 2016 08:00AM UCB Opens Solution Accelerator at Georgia Tech Technology Square
Sep 19, 2016 06:38AM Amgen (AMGN), UCB Announce Significant Data from Romosozumab Phase 3 in Osteoporosis
Sep 18, 2016 11:00AM Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
Sep 13, 2016 08:07AM Neuropore Therapies (NPT) Announces Achievement of Key Program Milestone
Jul 22, 2016 06:09AM Amgen (AMGN), UCB Submit Romosozumab BLA to U.S. FDA as Osteoporosis Treatment
Jul 22, 2016 01:00AM Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
Apr 1, 2016 04:01PM Amgen (AMGN), UCB Phase 3 Data Comparing Romosozumab With Teriparatide Presented at ENDO
Apr 1, 2016 04:00PM Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
Mar 21, 2016 06:22AM Amgen (AMGN), UCB Announce Romosozumab Phase 3 Met Primary Endpoint in Men With Osteoporosis
Mar 21, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Feb 22, 2016 06:21AM Amgen (AMGN), UCB Announce FRAME Phase 3 Met co-Primary Endpoints; One Secondary Endpoint Missed
Feb 22, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Feb 19, 2016 12:42PM U.S. FDA approves UCB's new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures
Dec 4, 2015 01:00AM UCB reinforces its commitment to epilepsy research with a strong presence at the 2015 American Epilepsy Society annual meeting
Nov 6, 2015 09:00AM UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting
Oct 12, 2015 04:01PM New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide
Sep 1, 2015 04:01PM Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide
Jul 1, 2015 03:00AM UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services
Jun 16, 2015 09:00AM New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.
May 16, 2015 09:30AM UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015
View More Recent Stories